Genmab — Maj 2019

[StockBull]

Kan selvfølgelig også være de mener det er en god case og de vil holde positionen de næste +5 år

[peter12]

Interessant læsning om asct ifm Cassiopeia https://uihc.org/health-topics/tandem-autologous-transplant-treatment

[gentogen]

Tak for opdatering om Duobody (super godt) og andet interessant. Var der ikke på et tidspunkt to BioNTech studier på CT? Synes kun jeg finder et og at Genmab kun nævner et (link 8.18).

[E_L]

GEN1042 seems to have disappeared, also from clinicaltrials, that was the CD40x4-1BB

[E_L]

i remember Sukkeralf writing he was already worried about this one,..

[E_L]

ClinicalTrials.gov

(clinicaltrials.gov)

[Bulder]

Vil det sige, at de har droppet cd40x4-1bb? Carlsen var fortrøstningsfuld så sent som Q&A.

[Bulder]

Måske bare forsinket, så de har pillet den af fact sheet, hjemmeside og CT.

[Bulder]

Den er stadig nævnt på fact sheet i højre side.

[Bulder]

https://ir.genmab.com/static-files/2541bd13-afb9-4c9d-91c4-7ec4c3b0fdc6

[ROI_-_David_Mygind]

For dem der hænger ud på chatten på en høj-hellig dag som i dag er her et sneak peak på noget jeg roder lidt med: http://bit.ly/genmab-industry-dynamics

[Helge_LarsenPI-redaktør]

God morgen.

[E_L]

Torben Plesner : " I continue with daratumumab monotherapy as a maintenance strategy "forever" " https://twitter.com/MM_Hub/status/1129414362874163200

[E_L]

i think maybe i should repeat an earlier link nobody reacted to

[E_L]

2/5 10:19
af E L
Usmani - Daratumumab as Frontline Treatment for Multiple Myeloma - https://www.youtube.com/playlist?list=PLZRBUfZtYYA9r0cx7Qo2psrJ9wi2sJg7A

[E_L]

2/5 12:35
af E L
Do I understand this correct, from Usmani video 3, that the Lenalidomide dosing in the experimental arm turned out to be 76% of the dosing of the standard care arm

[E_L]

Ola Landgren, M.D.
@DrOlaLandgren

https://twitter.com/DrOlaLandgren/status/1129544139215912960

[E_L]

Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among refractory patients https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.32178

[E_L]

A Multiple Myeloma Roundtable: Treatment Trends and Recent Clinical Advances http://obroncology.com/article/a-multiple-myeloma-roundtable-treatment-trends-and-recent-clinical-advances/#

[Bulder]

Yes, they have reduced dose of len more frequently in the exp-arm than in soc-arm. They have also done this earlier with pom. At least in the first cycle or two. I suppose it is due to side effects.